Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
High protein, anti-inflammatory, micronutrient-dense
Active Ingredient Cagrilintide 5mg + Semaglutide 5mg (lyophilized) Strength Tier Research-grade only Time to Results Not applicable (research use) Sun Sensitivity Not applicable research peptide Regulatory Status Research use only not for human consumption Cycling / Off Period Per study protocol not for human cycling Best For Licensed laboratory researchers studying dual amylin and GLP-1 receptor pathways in controlled in-vitro or preclinical settings
Regulatory Frameworks and Supply Dynamics: In December 2025, the FDA approved the first oral GLP-1 for weight loss-Novo Nordisk's once-daily semaglutide pill, which launched in January 2026, significantly expanding accessibility for patients averse to injections [3]
The drug is a modified version of human GLP-1, with a fatty acid chain attached that allows it to bind to albumin in the blood, extending its duration compared to natural GLP-1 (which lasts only minutes)
US$ 23.02
US$ 20.69
US$ 29.61
US$ 26.82
